New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages S117-S131

  Durantel, David ^a,b   Zoulim, Fabien ^a,b,c,d  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

Direct acting antivirals (DAA); Hepatitis B virus; Host targeting antivirals (HTA); Immunotherapy; Viral targets

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; TOLL LIKE RECEPTOR AGONIST; VESATOLIMOD; VIRUS ENVELOPE PROTEIN; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CELL THERAPY; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; DRUG TARGETING; GENE SILENCING; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; VACCINATION; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; HEPATITIS B, CHRONIC; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; VIRUS REPLICATION;

EID: 85010842062     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.016     Document Type: Review

References (106)

1. [1] Villain, P., Gonzalez, P., Almonte, M., Franceschi, S., Dillner, J., Anttila, A., et al. European code against cancer 4th edition: infections and cancer. Cancer Epidemiol 39 (2015), S120–S138.
2. [2] Chan, S.L., Wong, V.W., Qin, S., Chan, H.L., Infection and cancer: the case of hepatitis B. J Clin Oncol 34 (2016), 83–90.
3. [3] El-Serag, H.B., Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 2012, e1.
4. [4] Zoulim, F., Durantel, D., Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med, 5, 2015, 10.1101/cshperspect.a021501 pii: a021501.
5. [5] Gish, R.G., Given, B.D., Lai, C.-L., Locarnini, S.A., Lau, J.Y.N., Lewis, D.L., et al. Chronic hepatitis B: Virology, natural history, current management and a glimpe at future opportunities. Antiviral Res 121 (2015), 47–58.
6. [6] Papatheodoridis, G.V., Chan, H.L., Hansen, B.E., Janssen, H.L., Lampertico, P., Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 62 (2015), 956–967.
7. [7] Seeger, C., Zoulim, F., Mason, W.S., Hepadnaviruses. Knipe, D.M., Howley, P.M., (eds.) Field's virology, vol. 2, 2015, Lippincott Williams & Wilkins, Philadelphia, 2185.
8. [8] Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
9. [9] Bertoletti, A., Ferrari, C., Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61 (2012), 1754–1764.
10. [10] Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 64 (2015), 1314–1326.
11. [11] Rizzetto, M., Hepatitis D virus: introduction and epidemiology. Cold Spring Harb Perspect Med, 5, 2015, 10.1101/cshperspect.a021576 Pii: a021576.
12. [12] Yurdaydin, C., Idilman, R., Therapy of delta hepatitis. Cold Spring Harb Perspect Med, 5, 2015, 10.1101/cshperspect.a021543 pii: a021543.
13. [13] Alfaiate, D., Dény, P., Durantel, D., Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral Res 122 (2015), 112–129.
14. [14] Taylor, J.M., Hepatitis D virus replication. Cold Spring Harb Perspect Med, 5, 2015, 10.1101/cshperspect.a021568 pii: a021568.
15. [15] Clark, D.N., Hu, J., Hepatitis B virus reverse transcriptase – Target of current antiviral therapy and future drug development. Antiviral Res 123 (2015), 132–137.
16. [16] Tavis, J.E., Lomonosova, E., The hepatitis B virus ribonuclease H as a drug target. Antiviral Res 118 (2015), 132–138.
17. [17] Murakami, E., Wang, T., Park, Y., Hao, J., Lepist, E.-I., Babusis, D., et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 59 (2015), 3563–3569.
18. [18] Lu, G., Lomonosova, E., Cheng, X., Moran, E.A., Meyers, M.J., Le Grice, S.F.J., et al. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob Agents Chemother 59 (2015), 1070–1079.
19. [19] Gruffaz, M., Testoni, B., Luangsay, S., Fusil, F., Malika, A.G., Mancip, J., et al. The nuclear function of Hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes. Hepatology, 58, 2013 276A–276A.
20. [20] Guo, Y.H., Li, Y.N., Zhao, J.R., Zhang, J., Yan, Z., HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics 6 (2011), 720–726.
21. [21] Li, H.-C., Huang, E.-Y., Su, P.-Y., Wu, S.-Y., Yang, C.-C., Lin, Y.-S., et al. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog, 6, 2010, e1001162.
22. [22] Hadziyannis, S.J., Lieberman, H.M., Karvountzis, G.G., Shafritz, D.A., Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBcAg Vs. Anti-HBe positive carriers of hepatitis B virus. Hepatology 3 (1983), 656–662.
23. [23] Belloni, L., Li, L.C., Palumbo, G.A., Chirapu, S.R., Calvo, L., Finn, M., et al. HAPs hepatitis B virus (HBV) capsid inhibitors block core protein interaction with the viral minichromosome and host cell genes and affect cccDNA transcription and stability. Hepatology, 58, 2013 277A–277A.
24. [24] Selzer, L., Zlotnick, A., Assembly and release of hepatitis B virus. Cold Spring Harb Perspect Med, 5, 2015, 10.1101/cshperspect.a021394 pii: a021394.
25. [25] Delaney, W.E., Edwards, R., Colledge, D., Shaw, T., Furman, P., Painter, G., et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 46 (2002), 3057–3060.
26. [26] Deres, K., Schroder, C.H., Paessens, A., Goldmann, S., Hacker, H.J., Weber, O., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299 (2003), 893–896.
27. [27] Zlotnick, A., Venkatakrishnan, B., Tan, Z., Lewellyn, E., Turner, W., Francis, S., Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res 121 (2015), 82–93.
28. [28] Billioud, G., Pichoud, C., Puerstinger, G., Neyts, J., Zoulim, F., The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res 92 (2011), 271–276.
29. [29] Wang, X.Y., Wei, Z.M., Wu, G.Y., Wang, J.H., Zhang, Y.J., Li, J., et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 17 (2012), 793–803.
30. [30] Lam, A., Ren, S., Vogel, R. et al., Inhibition of hepatitis B virus replication by the HBV core inhibitor NVR 3-778. In: 66th annual meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, CA; 2015. Hepatology 62(Suppl. 1):223A–223A.
31. [31] Marcellin, P., Gane, E.J., Flisiak, R., Manns, M.P., Kaita, K.D., Gaggar, A., et al. Evidence for ongoing low-level viremia in patients with chronic hepatitis B receiving Long-term Nucleos(t)ide analog therapy. Hepatology, 60, 2014 1093A–1093A.
32. [32] Lucifora, J., Arzberger, S., Durantel, D., Belloni, L., Strubin, M., Levrero, M., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55 (2011), 996–1003.
33. [33] Bouchard, M.J., Navas-Martin, S., Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 305 (2011), 123–143.
34. [34] Gish, R.G., Yuen, M.F., Chan, H.L., Given, B.D., Lai, C.L., Locarnini, S.A., et al. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res 121 (2015), 97–108.
35. [35] Bazinet, M., Pantea, V., Cebotarescu, V., et al. Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV/HDV co-infection in Caucasian patients. In: 66th annual meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San Francisco, CA; 2015. Hepatology 62(Suppl. 1): 222A–222A.
36. [36] Yuen, M.-F., Chan, H.L.-Y., Liu, S.H.K., et al. ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B. Hepatology, 62, 2015 1385A–1385A.
37. [37] Billioud G, Kruse RL, Carrillo M, Whitten-Bauer C, Gao D, Kim A, et al. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J Hepatol 2016;64:781–789.
38. [38] Jansen, L., Vaillant, A., Stelma, F., Kootstra, N.A., Bazinet, M., Al-Mahtab, M., et al. Serum HBV-RNA Levels Decline Significantly In Chronic Hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA. J Hepatol, 62, 2015 S250–S250.
39. [39] Zoulim, F., Saputelli, J., Seeger, C., Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68 (1994), 2026–2030.
40. [40] Decorsière, A., et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 2016. http://dx.doi.org/.10.1038/nature17170.
41. [41] Cai, D., Mills, C., Yu, W., Yan, R., Aldrich, C.E., Saputelli, J.R., et al. Identification of the disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother, 2012.
42. [42] Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
43. [43] Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology 2016;150:194–205.
44. [44] Kennedy, E.M., Kornepati, A.V.R., Cullen, B.R., Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Res 123 (2015), 188–192.
45. [45] Ahmed, M., Wang, F., Levin, A., Le, C., Eltayebi, Y., Houghton, M., et al. Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. Drug Discovery Today 20 (2015), 548–561.
46. [46] Seeger, C., Sohn, J.A., Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids, 3, 2014, e216.
47. [47] Nelson, C.E., Hakim, C.H., Ousterout, D.G., Thakore, P.I., Moreb, E.A., Rivera, R.M.C., et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351 (2016), 403–407.
48. [48] Urnov, F., Genome editing: The domestication of Cas9. Nature 529 (2016), 468–469.
49. [49] Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 1, 2012, e00049.
50. [50] Urban, S., Bartenschlager, R., Kubitz, R., Zoulim, F., Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology, 2014.
51. [51] Lutgehetmann, M., Mancke, L.V., Volz, T., Helbig, M., Allweiss, L., Bornscheuer, T., et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55 (2012), 685–694.
52. [52] Belloni, L., Allweiss, L., Guerrieri, F., Pediconi, N., Volz, T., Pollicino, T., et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122 (2012), 529–537.
53. [53] Ebert, G., Preston, S., Allison, C., Cooney, J., Toe, J.G., Stutz, M.D., et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci U S A 112 (2015), 5797–5802.
54. [54] Ebert, G., Allison, C., Preston, S., Cooney, J., Toe, J.G., Stutz, M.D., et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci U S A 112 (2015), 5803–5808.
55. [55] Fulda, S., Promises and challenges of Smac Mimetics as cancer therapeutics. Clin Cancer Res 21 (2015), 5030–5036.
56. [56] Ferrari, C., HBV and the immune response. Liver Int 35 (2015), 121–128.
57. [57] Tan, A., Koh, S., Bertoletti, A., Immune response in hepatitis B virus infection. Cold Spring Harb Perspect Med, 5, 2015.
58. [58] Martinet, J., Dufeu-Duchesne, T., Bruder Costa, J., Larrat, S., Marlu, A., Leroy, V., et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143 (2012), 1586–1596.e8.
59. [59] Schuch, A., Hoh, A., Thimme, R., The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection. Front Immunol, 5, 2014, 258.
60. [60] Lampertico, P., Liaw, Y.F., New perspectives in the therapy of chronic hepatitis B. Gut 61 (2012), i18–i24.
61. [61] Marcellin, P., Ahn, S.H., Ma, X., Caruntu, F.A., Tak, W.Y., Elkashab, M., et al. Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology, 2015.
62. [62] Thimme, R., Dandri, M., Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?. J Hepatol 58 (2013), 205–209.
63. [63] Isorce, N., Lucifora, J., Zoulim, F., Durantel, D., Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. Antiviral Res 122 (2015), 69–81.
64. [64] van der Aa, E., van Montfoort, N., Woltman, A.M., BDCA3+CLEC9A+ human dendritic cell function and development. Semin Cell Dev Biol 41 (2015), 39–48.
65. [65] Dalod, M., Chelbi, R., Malissen, B., Lawrence, T., Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. EMBO J 33 (2014), 1104–1116.
66. [66] Zoulim, F., Luangsay, S., Durantel, D., Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B. Gastroenterology 144 (2013), 1342–1344.
67. [67] Testoni, B., Durantel, D., Lebosse, F., Fresquet, J., Helle, F., Negro, F., et al. Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut, 2015.
68. [68] Lanford, R.E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V.L., Brasky, K.M., et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144 (2013), 1508–1517.
69. [69] Menne, S., Tumas, D.B., Liu, K.H., Thampi, L., AlDeghaither, D., Baldwin, B.H., et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol 62 (2015), 1237–1245.
70. [70] Gane, E.J., Lim, Y.-S., Gordon, S.C., Visvanathan, K., Sicard, E., Fedorak, R.N., et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol, 2015.
71. [71] Cui, X., Clark, D.N., Liu, K., Xu, X.-D., Guo, J.-T., Hu, J., Viral DNA-dependent induction of innate immune response to hepatitis B virus in immortalized mouse hepatocytes. J Virol 90 (2015), 486–496.
72. [72] Luangsay, S., Ait-Goughoulte, M., Michelet, M., Floriot, O., Bonnin, M., Gruffaz, M., et al. Expression and Functionality of Toll- and RIG-like receptors in HepaRG Cells. J Hepatol 63 (2015), 1077–1085.
73. [73] Isogawa, M., Robek, M.D., Furuichi, Y., Chisari, F.V., Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79 (2005), 7269–7272.
74. [74] Guo, F., Han, Y., Zhao, X., Wang, J., Liu, F., Xu, C., et al. STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. Antimicrob Agents Chemother 59 (2015), 1273–1281.
75. [75] Lucifora, J., Maadadi, S., Floriot, O., Daffis, S., Fletcher, S., Zoulim, F., et al. Direct antiviral effects of various pattern recognition receptor (PRR) agonists in HBV-replicating hepatocytes. J Hepatol 62 (2015), S515–S516.
76. [76] Visvanathan, K., Skinner, N.A., Thompson, A.J., Riordan, S.M., Sozzi, V., Edwards, R., et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45 (2007), 102–110.
77. [77] Zhang, X., Ma, Z., Liu, H., Liu, J., Meng, Z., Broering, R., et al. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 57 (2012), 522–528.
78. [78] Durantel, D., Zoulim, F., Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option?. J Hepatol 57 (2012), 486–489.
79. [79] Ries Carola, H., Cannarile Michael, A., Hoves, S., Benz, J., Wartha, K., Runza, V., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
80. [80] Cassier, P.A., Italiano, A., Gomez-Roca, C.A., Le Tourneau, C., Toulmonde, M., Cannarile, M.A., et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 16 (2015), 949–956.
81. [81] Pallett, L.J., Gill, U.S., Quaglia, A., Sinclair, L.V., Jover-Cobos, M., Schurich, A., et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med 21 (2015), 591–600.
82. [82] Barnes, E., Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol 204 (2015), 79–86.
83. [83] Michel, M.-L., Bourgine, M., Fontaine, H., Pol, S., Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?. Med Microbiol Immunol 204 (2015), 121–129.
84. [84] Zhang, E., Kosinska, A., Lu, M., Yan, H., Roggendorf, M., Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA. Antiviral Res 123 (2015), 193–203.
85. [85] Fontaine, H., Kahi, S., Chazallon, C., Bourgine, M., Varaut, A., Buffet, C., et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial—ANRS HB02 VAC-ADN. Gut 64 (2015), 139–147.
86. [86] Gaggar, A., Coeshott, C., Apelian, D., Rodell, T., Armstrong, B.R., Shen, G., et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study. Vaccine 32 (2014), 4925–4931.
87. [87] Plotkin, S.A., Schaffner, W., A hepatitis B vaccine with a novel adjuvant. Vaccine 31 (2013), 5297–5299.
88. [88] Bertoletti, A., Brunetto, M., Maini, M.K., Bonino, F., Qasim, W., Stauss, H., T cell receptor-therapy in HBV-related hepatocellularcarcinoma. OncoImmunology, 4, 2015, e1008354.
89. [89] Qasim, W., Brunetto, M., Gehring, A.J., Xue, S.-A., Schurich, A., Khakpoor, A., et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 62 (2015), 486–491.
90. [90] Ye, B., Liu, X., Li, X., Kong, H., Tian, L., Chen, Y., T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis, 6, 2015, e1694.
91. [91] Rehermann, B., Bertoletti, A., Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology 61 (2015), 712–721.
92. [92] Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 369 (2013), 122–133.
93. [93] Tzeng, H.-T., Tsai, H.-F., Liao, H.-J., Lin, Y.-J., Chen, L., Chen, P.-J., et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One, 7, 2012, e39179.
94. [94] Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog, 10, 2014, e1003856.
95. [95] Bengsch, B., Martin, B., Thimme, R., Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61 (2014), 1212–1219.
96. [96] Bono, M.R., Fernández, D., Flores-Santibáñez, F., Rosemblatt, M., Sauma, D., CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression. FEBS Lett 589 (2015), 3454–3460.
97. [97] Tang, Y., Jiang, L., Zheng, Y., Ni, B., Wu, Y., Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection. BMC Immunol, 13, 2012, 17.
98. [98] Wedemeyer, H., Yurdaydìn, C., Dalekos, G.N., Erhardt, A., Çakaloğlu, Y., Değertekin, H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364 (2011), 322–331.
99. [99] Heidrich, B., Yurdaydın, C., Kabaçam, G., Ratsch, B.A., Zachou, K., Bremer, B., et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60 (2014), 87–97.
100. [100] Heidrich, B., Yurdaydin, C., Kabacam, G., Ratsch, B.A., Zachou, K., Bremer, B., et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60 (2014), 87–97.
101. [101] Wedemeyer, H., Yurdaydin, C., Dalekos, G.N., Erhardt, A., Cakaloglu, Y., Degertekin, H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364 (2011), 322–331.
102. [102] Keskin, O., Wedemeyer, H., Tuzun, A., Zachou, K., Deda, X., Dalekos, G.N., et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol, 13, 2015, e2.
103. [103] Volz, T., Giersch, K., Allweiss, L., Bhadra, O.D., Petersen, J., Lohse, A.W., et al. Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stably HBV/HDV co-infected mice. J Hepatol, 62, 2015 S514–S514.
104. [104] Bogomolov, P., Voronkova, N., Allweiss, L., Dandri, M., Schwab, M., Lempp, F.A., et al. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology 60 (2014), 1279A–1280A.
105. [105] Palsuledesai, C.C., Distefano, M.D., Protein prenylation: enzymes, therapeutics, and biotechnology applications. ACS Chem Biol 10 (2015), 51–62.
106. [106] Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S.L., Haynes-Williams, V., et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15 (2015), 1167–1174.